Related Experiment Videos

The frequency of hypoglycemia in full-term large and small for gestational age newborns

P C Holtrop1

  • 1Department of Pediatrics, William Beaumont Hospital, Royal Oak, MI 48073-6769.

Insights

Screening for hypoglycemia in newborns requires specific durations: stop after 12 hours for large for gestational age (LGA) infants and continue for 48 hours for small for gestational age (SGA) infants.

Area of Science:

  • Neonatal Medicine
  • Pediatric Endocrinology
  • Clinical Chemistry

Background:

  • Limited data exist on hypoglycemia frequency and screening duration in large for gestational age (LGA) and small for gestational age (SGA) newborns.
  • Current recommendations for hypoglycemia screening in LGA and SGA infants lack precise duration guidelines based on recent definitions.

Purpose of the Study:

  • To determine the frequency of hypoglycemia in full-term LGA and SGA infants using a recent definition.
  • To establish the appropriate duration for hypoglycemia screening in these at-risk newborn populations.

Main Methods:

  • Blood glucose levels were measured using chromogen test strips at multiple time points (1-48 hours) in full-term LGA and SGA infants of non-diabetic mothers.
  • Serum glucose confirmation was performed for test strip readings below 40 mg/dl.
  • Hypoglycemia was defined based on serum glucose levels relative to infant age (<35 mg/dl at <3 hours, <40 mg/dl at 3-24 hours, <45 mg/dl at >24 hours).

Main Results:

  • Hypoglycemia occurred in 8.1% of LGA infants and 14.7% of SGA infants.
  • The mean age of hypoglycemia onset was 2.9 hours for LGA and 6.1 hours for SGA infants.
  • Risk factors like meconium-stained amniotic fluid, maternal preeclampsia, and male sex were more common in hypoglycemic SGA infants.

Conclusions:

  • Hypoglycemia screening in non-diabetic mothers' LGA infants can cease after 12 hours.
  • Continuous hypoglycemia screening for up to 48 hours is recommended for SGA infants.
  • These findings provide evidence-based guidelines for optimizing hypoglycemia surveillance in at-risk newborns.

Related Concept Videos